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The British Cardiac Society commissioned this report to
help address inconsistencies in the terminology for acute
coronary syndromes and wide variations in the threshold
for the diagnosis of myocardial infarction (MI) depending
on the assay performed, the precision, and the sensitivity.
In addition, several publications have highlighted potential
problems with the application of the European Society of
Cardiology(ESC)/American College of Cardiology (ACC)
consensus document published in 2000. A revision process
has been initiated under the guidance of the ESC, the ACC,
and the American Heart Association (AHA). The purpose
of this report is to help inform the next revision of the ESC/
ACC/AHA guidelines for the diagnosis of MI.
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cute coronary syndrome (ACS) describes a
spectrum of clinical manifestations that
result from a common pathophysiological
process. After rupture or erosion of an athero-
matous coronary plaque, intraluminal thrombo-
sis partially or completely obstructs the coronary
artery. The process is complicated by encroach-
ment of the disrupted coronary plaque into the
vessel lumen, by embolisation of fragments of
thrombus into the distal coronary circulation,
and by changes in vascular tone.
The clinical manifestations depend on the
volume of myocardium affected and by the
severity of ischaemia or myocardial necrosis.
Thus, the spectrum ranges from unstable angina
with ischaemia, but without detectable myocyte
necrosis, to ACS with variable degrees of myocyte
necrosis. The latter encompasses patients with a
typical clinical syndrome accompanied by ECG
changes and increased cardiac markers (tropo-
nins or creatine kinase (CK) MB) through to
those with extensive infarction complicated by
haemodynamic compromise and other major
complications (fig 1).
Patients with erosion or rupture of an athero-
matous coronary plaque may or may not go on to
develop myocardial infarction (MI). Whether
detectable infarction occurs depends on several
pathophysiological features such as the extent
and locus of plaque rupture, the nature of
thrombotic consequences, the presence of collat-
eral vessels, and the effectiveness and timing of
reperfusion. MI confers particular risks as a
result of impairment of left ventricular function
and mechanical and arrhythmic complications.
The label MI has important implications for
a patient’s occupation, disability claims, and
insurance. Thus, an accurate and consistent
diagnosis of infarction is critically important to
guide patient management and to provide robust
reference data in epidemiological studies, clinical
trials, and the coding of disease definitions
(International classification of diseases, Read,
SNOMED). An international group, led by the
European Society of Cardiology (ESC), American
College of Cardiology (ACC), and American
Heart Association (AHA), are further revising
the proposals published in 2000 for the definition
of MI. The input from the British Cardiac Society
(BCS) Working Group will help to inform the
revision.
World Health Organization definition of MI
Traditionally, MI has been diagnosed according
to the 1971 World Health Organization (WHO)
criteria (table 1) based on the clinical syndrome,
ECG changes, and increase of relatively non-
specific markers of myocardial damage such as
CK. The commonly accepted diagnostic threshold
of a twofold increase in CK above the laboratory
upper limit was not based on the absence of
histological evidence of infarction below this
arbitrary threshold but on the limited diagnostic
accuracy of the assay (wide interindividual and
intraindividual variation due the effects of
physical activity, ethnicity, and other factors).
Abbreviations: ACC, American College of Cardiology;
BCS, British Cardiac Society; CK, creatine kinase; ESC,
European Society of Cardiology; FRISC, fast
revascularisation during instability in coronary artery
disease; GRACE, global registry of acute coronary events;
MI, myocardial infarction; PCI, percutaneous coronary
intervention; PRAIS-UK, prospective registry of acute
ischaemic syndromes in the UK; SPECT, single photon
emission computed tomography; TIMI, thrombolysis in
myocardial infarction; WHO, World Health Organization
The remit of the British Cardiac Society
Working Group on MI is:
N To establish a nomenclature for acute
coronary syndromes to meet current treat-
ment and prognostic needs of patients
N To recommend a diagnostic threshold to
distinguish patients with MI from patients
with acute coronary syndromes with minor
but prognostically important increases of
troponin concentrations
N To recommend a strategy for establishing
a reference standard for troponin assays.
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ESC/ACC redefinition of MI
In 2000, a joint ESC/ACC committee published a redefinition
of MI1 (table 1) based on more sensitive and specific markers
of myocyte necrosis (troponins or CK-MB mass). The
consequence is that a substantially increased proportion of
patients with ACS will be classified as having had an MI by
the new ESC/ACC definition compared with the WHO
criteria. Both sets of criteria include ST elevation and non-
ST elevation MIs.
Prognosis in ACS and the need for consistent
definitions in ACS
Clinical trials and large scale registry programmes have
shown that the outcome for non-ST elevation MI is not
benign (12–13% death rate at six months in GRACE (global
registry of acute coronary events) and PRAIS-UK (prospec-
tive registry of acute ischaemic syndromes in the UK)) and is
similar to the six month survival of patients with ST elevation
MI who reach hospital alive.2 3 However, the time course and
nature of the cardiac consequences differ substantially.
Furthermore, patients with non-ST elevation MI at higher
risk may benefit particularly from acute interventional
strategies and certain pharmacological treatment (glyco-
protein IIb/IIIa inhibitors, low molecular weight heparin)
compared with patients with ACS who do not have increased
markers or other features of higher risk. Patients with a
clinical syndrome of ACS and an abnormal ECG but no
marker increase (‘‘unstable angina’’) do not have a benign
prognosis when the diagnosis is supported by evidence of
underlying ischaemic heart disease (5% death at six
months).2 3 Thus, more accurate delineation of risk by
sensitive cardiac markers is to be welcomed. However, the
inclusion within the classification ‘‘myocardial infarction’’ of
patients with a lesser volume of myocardial damage than was
previously detectable will affect comparisons with previous
reference studies and epidemiological cohorts.4 For example,
the impact of a lesser proportion of patients with MI with
Q wave infarctions will need to be defined in longitudinal
studies. Larger infarctions are particularly susceptible to the
long term hazards of ventricular remodelling and heart
Figure 1 Spectrum of acute coronary
syndrome (ACS). CK, creatine kinase;
LV, left ventricular; Tn, troponin. *Risk
of death is from hospitalisation to six
months.
Table 1 Criteria of the World Health Organization and the Joint European Society of
Cardiology/American College of Cardiology
World Health Organization criteria for MI
Definite acute MI
1. Definite ECG or
2. Symptoms typical or atypical or inadequately described, together with probable ECG or abnormal
enzymes or
3. Symptoms typical with abnormal enzymes with ischaemic or non-codable ECG or ECG not available or
4. Fatal case, whether sudden or not, with naked eye appearance of fresh MI, recent coronary occlusion found at
necropsy, or both
Joint European Society of Cardiology/American College of Cardiology criteria
Criteria for acute, evolving, or recent MI—one of the following:
1. Typical rise and fall of biochemical markers of myocardial necrosis with at least one of the following:
a) ischaemic symptoms
b) Q waves
c) ischaemic ECG changes
d) coronary artery intervention
2. Pathological findings of an acute MI
Criteria for established MI—any of the following:
1. Development of new pathological Q waves on serial ECGs
2. Pathological findings of a healed or healing MI
MI, myocardial infarction.
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failure. This has important implications for patients who may
unjustifiably be given prognostic information based on
historical comparisons, are barred from certain occupations,
and are inappropriately penalised or rewarded by financial
and insurance institutions. Ongoing epidemiological studies
will need also to take account of the new threshold for
diagnosis of MI.
The advent of more sensitive assays of myocyte necrosis
has given rise to a confusion of terminology to describe
patients with ACS with a troponin increase but no ST
elevation or bundle branch block: ‘‘non-ST elevation MI’’,
‘‘troponin positive ACS’’, ‘‘minor myocardial damage’’,
‘‘prognostically important unstable angina’’, ‘‘necrosette’’,
or even ‘‘troponitis’’. Clarification and consistency of termi-
nology are required.
Stratification of risk in ACS
Binary approaches to stratifying risk in patients with ACS
lack sufficient precision: simply separating patients into
troponin positive or negative groups as the sole method of
determining higher or lower risk is insufficiently sensitive.
N Troponin increase should be regarded as only one of
the independent predictors of risk in patients with
ACS.
More reliable and extensively tested predictors include the
TIMI (thrombolysis in myocardial infarction) risk score
(table 2)5 and the GRACE risk score (table 3).6
The GRACE risk model was derived from 12 500 patients
across the spectrum of ACS and validated externally. It
accurately predicts death (or death/MI) in hospital and at six
months.6 The TIMI and GRACE risk scores show that a
marker increase is only one of several multivariate predictors
of adverse outcomes.
N More robust risk prediction requires the integration
of all of the key risk predictors.
Variations in diagnostic accuracy of assay systems
An important issue to be considered in the ESC/ACC
diagnosis of MI concerns the differences in sensitivity and
diagnostic accuracy between troponin assays. Thus, in two
laboratories in the same city (or even the same institution
when ‘‘point of care’’ and laboratory assays are both used) a
patient’s condition may satisfy the diagnosis of MI in one
assay system but not the other. The more sensitive and
precise the assay system, the larger the proportion of patents
who will fulfil the ESC/ACC definition of MI.7 A robust
reference standard for troponin assays and a defined and
consistent threshold and nomenclature for those with marker
increases are needed. Experimental studies of coronary artery
occlusion show that troponin concentrations 96 hours after
occlusion accurately reflect infarct size (p = 0.001,
r = 0.74).8
PROPOSED NOMENCLATURE FOR ACS
While recognising the common pathophysiological mechan-
isms across the spectrum of ACS, we determine the clinical
and cardiac marker manifestations by the volume of
myocardium affected and the severity of ischaemia. Despite
the similarities in disease mechanism the time course and
severity of cardiac complications vary substantially across the
spectrum of ACS. Similarly, treatment patterns differ.
The Working Group proposes that the spectrum of
ACS should be subdivided as follows:
N ACS with unstable angina
N ACS with myocyte necrosis
N ACS with clinical MI.
The Working Group recommends that the term ‘‘unstable
angina’’ should be reserved for patients with a clinical
syndrome, but with undetectable troponin or CK-MB
markers. Unstable angina requires supporting evidence of coronary
disease (abnormal ECG or prior documented coronary disease).
The term ‘‘clinical myocardial infarction’’ should be
reserved for patients in the context of a typical clinical
syndrome and a marker increase above the diagnostic thresh-
old. The Working Group proposes that the threshold for
defining clinical MI be set at 1.0 ng/ml for troponin T or
0.5 ng/ml for AccuTnI (or equivalent threshold with other
troponin I methods). This recommendation is made on the
basis that the risk of death is similar to that seen with CK
increase of 400 U/l (troponin T) and comparison with WHO
definitions (AccuTnI troponin I, see below). The extent of left
ventricular dysfunction is also similar to that seen with a CK
increase of > 400 U/l (C Knight and A Timmis, personal
communication). A troponin T increase . 2.8 ng/ml predicts
a left ventricular ejection fraction of , 40% after MI
(sensitivity 100%, confidence interval 84.6 to 100).14 The
specificity is 92.9% (confidence interval 76.5 to 89.1). These
finding were irrespective of whether or not thrombolysis was
used.
An analysis has been performed of 804 patients admitted
with ACS with both troponin T and CK results (A Timmis
et al, personal communication, 2004). Patients classified as
having had an MI according to traditional criteria (CK
. 400 U/l) had an inpatient mortality of 8.4% with a
combined incidence of death and left ventricular failure of
27.2%. Risk stratification of the entire cohort of patients
according to the troponin T concentration showed a gradient of
risk ranging from an inpatient mortality of 1.8% for patients
with a normal troponin to 8% for patients with a troponin
concentration in the highest tertile (> 1.1 ng/ml). As table 4
shows, in this group a troponin concentration > 1.1 ng/ml
Table 3 GRACE (global registry of acute
coronary events) risk score: independent
predictors of death among patients presenting
with the spectrum of ACS based on widely
available clinical and biological markers
l Age (a continuous variable)
l Killip class (heart failure)
l Arterial blood pressure
l ST deviation on ECG
l Cardiac arrest
l Increased creatinine concentration
l Increased CK-MB or troponin concentration
l Heart rate
Each characteristic is included in the nomogram (or PDA
programme) and a numerical risk of death (or death/MI) is
provided.
C index for death 0.84 (Granger et al,6 www.outcomes.org/
grace).
CK, creatine kinase.
Table 2 Components of the TIMI (thrombolysis in
myocardial infarction) risk score
l Age .65 years
l History of diabetes, hypertension, or angina
l Documented coronary stenosis .50%
l ST deviation
l >2 anginal events in the proceeding 24 hours
l Aspirin treatment in the prior seven days
l Increased cardiac markers
l More prior congestive heart failure or more MI, coronary artery
bypass grafting, or percutaneous coronary intervention
Each characteristic qualifies for one point in the risk score.
Data from Antman et al.5
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approximates to the traditional definition of MI in terms of in-
hospital outcome.
The decision value for AccuTnI is based on a multicentre
study of 328 patients, of whom 74 had AMI defined by WHO
criteria. The use of troponin I . 0.5 ng/ml gave optimal
sensitivity (96%) and specificity (94%) (R Rossington,
Beckman Coulter, personal communication, 2003).
The term ‘‘ACS with myocyte necrosis’’ should be reserved
for patients with a typical clinical syndrome plus an increased
troponin concentration below the diagnostic threshold (that
is, troponin T , 1.0 ng/ml or AccuTnI , 0.5 ng/ml). It is
recognised that such patients have an adverse prognosis
including increased risk of death compared with patients
with unstable angina without an increased marker.
Nevertheless, the distribution of their subsequent coronary
events differs from that of patients with a clinical MI: the
events continue over time resulting in further hospitalisation
and infarction, whereas after clinical MI there is a clustering
of events around the initial presentation including risk of
death, ventricular arrhythmias, and heart failure.
N TheWorking Group recommends that in the context
of a typical ACS clinical myocardial infarction should
be diagnosed when the maximum troponin T
increase is . 1.0 ng/ml or AccuTnI . 0.5 ng/ml
(and/or new Q waves develop on the ECG).
Individual laboratories that use other troponin I
assays will need to estimate an equivalent troponin I
concentration.
The Working Group recommends that patients with an
ACS and myocyte necrosis as evident by detectable troponin
(that is, troponin T , 1.0 ng/ml or AccuTnI , 0.05 ng/ml)
should be deemed to have ACS with myocyte necrosis.
A REFERENCE STANDARD FOR TROPONIN ASSAYS
There are insufficient data to compare measurements
accurately between troponin assays. It is anticipated that
this will change when a robust reference standard for the
troponin assays is prepared. The International Federation for
Clinical Chemistry is addressing this issue and hopes to
report reference standards for troponins in 2004. The
Working Group recommends that the BCS adopt this
international reference standard when it becomes available.
TROPONIN INCREASE IN PATIENTS WITHOUT ACS
False positive results
False positive results may be found when the true troponin
concentration lies close to the diagnostic threshold, but the
assay lacks sufficient precision. If the assay precision is poor
(that is, the coefficient of variation is large), then by the play
of chance a number of true negative results will appear
‘‘positive’’ and vice versa.
This problem may be resolved by using later generations of
troponin assays with sufficient precision at the decision
making points (that is, , 10% coefficient of variation at the
99th centile upper limit for normal). This will ensure greater
confidence in the diagnostic threshold, which will be well
separated from the upper limit for normal.8–12 Many of the
earlier generation assays do not meet this level of predictive
accuracy yet may still be used in current practice (A Reid
SEQAS, personal communication, 2003).
N The Working Group recommends that all British
hospital laboratories should review their troponin
assays to ensure that they meet the ESC/ACC
recommendations for precision.
Other causes of myocyte necrosis
Patients with pulmonary embolism, myocarditis, or heart
failure may have increased troponin concentrations but
without other features of ACS. Nevertheless, studies have
shown that the extent of myocyte necrosis in such patients
predicts adverse outcome. In patients with renal insufficiency
increased troponins are also associated with adverse outcome
but the mechanisms are complex and include altered
clearance of troponins.
N A variety of conditions cause myocyte necrosis and
this may be reflected accurately by troponin
increase, despite the fact that such patients have
not experienced an ACS.
DIAGNOSIS OF MI WITH NUCLEAR IMAGING
TECHNIQUES
Single photon emission computed tomography (SPECT)
myocardial perfusion imaging is an established procedure
for the diagnosis for infarction but has relatively limited
spatial resolution of about 106 106 10 mm (full width half
maximum resolution). In contrast, cardiac magnetic reso-
nance with late gadolinium enhancement is more sensitive
than SPECT, especially for the detection of smaller sub-
endocardial infarctions representing 1–10% of left ventricular
volume.12–14 The spatial resolution of cardiac magnetic
resonance is about 60-fold greater than SPECT (1.46
1.96 6.0 mm). Nevertheless, neither of these imaging
techniques can distinguish recent from prior infarction.
TROPONIN INCREASES IN PATIENTS UNDERGOING
REVASCULARISATION PROCEDURES
Percutaneous coronary intervention
It is well recognised that the myocardium can be damaged
after percutaneous coronary intervention (PCI) and cardiac
markers may increase in up to a third of patients.10–13 In the
majority of cases this is of a minor degree. Causes include
side branch occlusion and microembolisation. It is important
to bear in mind, just as with spontaneous MI, that cardiac
enzyme release after PCI should be integrated with clinical,
angiographic, and ECG data to assess prognosis properly.
Troponin concentrations should not be considered in
isolation.
However, it is clear from several studies that patients with
increased cardiac markers after PCI have an adverse short
term prognosis and that the risk of adverse events increases
Table 4 Complication rates by cardiac troponin tertile
Cardiac troponin T (ng/ml)
CK .400 U/l(0.01 (n = 338) Tertile 1: (0.26 (n = 159) Tertile 2: (1.1 (n = 156) Tertile 3: >1.1 (n = 151)
LVF 33 (9.9%) 24 (15.1%) 29 (18.6%) 6 (23.8%) 61 (24.5%)
Death 6 (1.8%) 2 (1.3%) 6 (3.9%) 12 (8%) 21 (8.4%)
Death/LVF 36 (10.7%) 24 (15.1%) 30 (19.2%) 41 (27.2%) 68 (27.2%)
For the upper tertile of cardiac troponin T the risk of left ventricular failure (LVF), death, and combined death/LVF was significantly greater than in all the other
groups.
All p,0.003.
606 Fox, Birkhead, Wilcox, et al
www.heartjnl.com
with the degree of marker increase.15–24 The longer term
significance of small increases of cardiac enzymes after PCI
are less certain, whereas marker release of a greater degree is
known to have an adverse impact on long term prognosis.23 24
Given this evidence there is no obvious reason why there
should be different thresholds for cardiac enzyme release for
spontaneous and periprocedural MI. A definition of MI
independent of whether the myocardial damage occurred
spontaneously or after PCI will also allow a better comparison
to be made between medical, interventional, and surgical
treatments for coronary artery disease. The impact of cardiac
enzyme release after PCI on prognosis reinforces the
importance of regular, protocol driven measurement of
cardiac markers after these procedures. In many cases,
detection of an increased marker will not require specific
treatment, but without recognition of the phenomenon
proper audit is not possible and advances in preventing
myocardial damage during revascularisation procedures are
unlikely to be made.
N The Working Group recommends systematic mea-
surement of troponins after PCI (. 6 hours) as part
of quality control standards.
CORONARY ARTERY BYPASS GRAFTING
After major vascular surgery about 3% of patients experience
clinically evident MI based on WHO criteria, but with routine
monitoring of troponin or CK-MB, MI is detected in about
12% of patients.23 Similar findings are likely to apply with
coronary artery bypass grafting, but the situation is compli-
cated by the release of cardiac markers caused by surgical
instrumentation of coronary vessels. Nevertheless, a direct
relation exists between the extent of enzyme and marker
release and subsequent mortality. In a study from the Mid
America Heart Institute, CK-MB increase after coronary
artery bypass grafting was an independent predictor of long
term mortality, but there appears to be a threshold at about
four times the upper limit of normal for CK-MB.25 On the
basis of these and other publications routine evaluation of
the ECG and cardiac markers after coronary artery bypass
grafting is likely to provide useful information on longer term
prognosis and on improvement in quality control standards.
DETECTION OF REINFARCTION
Reinfarction and coronary reocclusion after initially success-
ful reperfusion are underrecognised on account of the
reduced sensitivity of the ECG in the context of a recent
acute infarction and the possibility that enzymes and cardiac
markers have not returned to baseline values. Within the first
12–24 hours of an infarction the detection of reinfarc-
tion relies on clinical symptoms plus re-elevation of the
ST segments in the affected territory of the ECG.
Subsequently, a rise in cardiac markers to . 50% above a
previous peak concentration has been used in clinical trials as
an objective criterion of reinfarction. The long half life of
troponins reduces their sensitivity for the detection of
reinfarction in the days after an index MI. Shorter half life
markers (CK-MB, myoglobin, or cardiac fatty acid binding
protein) and agreed thresholds are required to allow
consistent and more sensitive detection of reinfarction. CK
is less specific but may be used to detect reinfarction before
more specific markers are tested.
CONCLUSIONS
The Working Group recommends that patients with an ACS
should be categorised as being either without detectable
increases in cardiac troponins (ACS with unstable angina) or
with myocyte necrosis but troponin increases less than the
diagnostic threshold for clinical infarction (troponin T
, 1.0 ng/ml, AccuTnI , 0.5 ng/ml, or equivalent other
troponin I concentrations), or they should be categorised as
having clinical MI when the ECG signs are accompanied by
troponin (and or CK-MB) increases above the diagnostic
threshold for infarction.
On initial presentation, a working diagnosis of suspected
ST elevation infarction is important and urgent, as such
patients require emergency reperfusion. Initial presentation
with ST elevation is highly specific for subsequent MI but if
reperfusion occurs very promptly or spontaneously, infarction
may be attenuated and in a small proportion of patients may
not be detectable.
Outside of the context of ACS, troponin increase may
nevertheless reflect myocyte necrosis and may provide
prognostic information. Such conditions should not be
confused with ACS.
In the context of ACS, a continuous relation exists between
the extent of troponin increase and the extent of MI.
Nevertheless, the Working Group recognises that identifica-
tion of clinically evident MI is useful, as it identifies patients
with increased risks of death and more notable evidence of
left ventricular dysfunction. The Working Group suggests a
threshold of troponin T . 1.0 ng/ml or AccuTnI . 0.5 ng/ml
(or equivalent concentrations in other troponin assays) for
recognising clinical MI.
The Working Group recommends that all hospital labora-
tories should ensure that troponin assays meet accuracy
standards set out in the ESC/ACC recommendations.1 11
Further, the Working Group strongly recommends that
British hospitals should adopt the international reference
standard for comparing troponin assays as soon as this
becomes available.
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APPENDIX 2
REVIEW OF STUDIES COMPARING TROPONIN
ASSAYS IN RELATION TO OUTCOME
The problem with the interpretation of troponin assays is due
to many factors including the lack of standardisation and
variable analytical performance by the different methods.
These factors have led to confusion over the use of a value
that can be universally used as a decision point.
Troponin T assays are made by only a single manufacturer
and therefore all values are comparable. However, troponin I
assays are made by many different manufacturers and, as
they use different formulations and standards, results
obtained by different methods cannot be compared.
The International Federation of Clinical Chemistry is
developing a standard that can be used to help harmonise
methods. Until this preparation is available, each method
needs to be evaluated. One option for this is to examine the
outcome. This is probably the best option despite the current
rapid change in treatment regimens.
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Table 5 Bayer ACS180 versus Roche Elecsys 1010:
data from Morrow et al 26
Troponin assay and
concentration (ng/ml)
Death at
30 days
Death at 6
and 12 months
Elecsys TnT .0.01 2.6% 4.0%
Elecsys TnT .0.1 2.9% 4.3%
ACS 180 TnI .0.1 2.4% 3.9%
ACS 180 TnI .1.5 2.6% 3.8%
TnI, troponin I; TnT, troponin T.
Table 6 Data from Morrow et al 27
Troponin assay and
concentration (ng/ml)
Death at
30 days
Death/MI at 6
and 12 months
BC AccuTnI ,0.04 0.5% 3.3%
BC AccuTnI .0.04 2.0% 9.0%
Table 7 Data from Morrow et al 28
Troponin assay and concentration
(ng/ml)
Death at
43 days
Death/MI at
43 days
Dimension RxL TnI .0.1 5.1% 13.3%
ACS180 TnI .0.1 5.4% 13.7%
Immuno 1 TnI .0.1 4.7% 12.9%
Table 9 Data from Venge et al 30
Troponin assay and
concentration (ng/ml)
Liaison cTnI
,0.041 ng/ml
Liaison cTnI
.0.041 ng/ml
BC AccuTnI ,0.04 5.6% 9.1%
BC AccuTnI .0.04 13.2% 14.0%
Acute MI or death at six months, n = 3456.
cTnI, cardiac troponin I.
Table 10 Data from Uettwiller-Geiger et al 31
Troponin assay equivalencies r Number
AccuTnI = 0.932 (¡0.029) Dade RxL21.039 0.980 147
AccuTnI = 1.109 (¡0.031) Vitros ECi20.473 0.968 316
AccuTnI = 0.183 (¡0.010) AxSYM+0.062 0.946 128
Poorer correlations are seen if only low concentrations (AccuTnI
,1.5 ng/ml) are used.
Table 8 Data from Venge et al 29
Troponin assay and
concentration (ng/ml)
Death with marker less than indicated in
column 1 at 1 year Death at 1 year
BC AccuTnI .0.02 0.7% 4.5%
BC AccuTnI .0.03 1.1% 4.5%
AxSym TnI .0.6 3.2% 4.1%
AxSym TnI .0.10 2.8% 4.3%
Elecsys TnT .0.01 1.7% 4.7%
Elecsys TnT .0.03 2.6% 4.4%
AxSYM ,1.0 ng/ml AxSYM .1.0 ng/ml
BC AccuTnI ,0.03 1.2% death at 1 year Insufficient data
BC AccuTnI .0.03 5.5% death at 1 year 4.4% death at 1 year
Table 11 Data from Lewis et al 32
Troponin assay and
concentration (ng/ml)
AxSYM
,0.6 ng/ml
AxSYM
.0.6 ng/ml
ACS:180 ,0.12 NA 20
ACS:180 .0.12 10 130
163 samples identified with low troponin—selection was biased as no
negatives were included; NA, data not available.
Table 12 Data from Venge et al 29
Troponin assay and
concentration (ng/ml) AxSYM ,1.0 ng/ml AxSYM .1.0 ng/ml
BC AccuTnI ,0.03 1.2% death (6.4% AMI/death) n = 3
BC AccuTnI .0.03 5.5% death (13.8% AMI/death) 4.4% death (17% AMI/death)
Elecsys TnT ,0.03 ng/ml Elecsys TnT .0.03 ng/ml
BC AccuTnI ,0.03 1.2% death (5.8% AMI/death) n = 2
BC AccuTnI .0.03 5.1% death (14.3% AMI/death) 4.5% death (16.8% AMI/death)
Clinical events at 1 year, n = 879.
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Table 14 UK National External Quality Assessment
Service between laboratory comparisons34; lowest
concentrations at which between laboratory coefficients of
variation are (10%
Assay Concentration (ng/ml)
TnI
Abbott AxSYM 4.4
Bayer Immuno 1 NA
Bayer Advia Centaur 1
Beckman Coulter AccuTnI 0.65
Dade Dimension 1.75
Dade Stratus 1.25
DPC Immulite NA
DPC Immulite 2000 2.75
Ortho CD Vitros ECi 2.0
Tosoh Bioscience AIA 7.5
TnT
Roche Elecsys 1010 0.25
Roche Elecsys 2010 0.33
Note that many manufacturers are changing and improving their assay
methods.
NA, not available.
NB: CV data on the Abbott AxSYM, Vitros Eci, and Tosoh AIA systems
are derived from ,10 data points.
Table 13 Data compared by Deming regression: data
from Kao et al 33
Troponin assay equivalencies r p Value
Immulite = 1.505 Vitros20.154 0.99 ,0.0001
Immulite = 0.288 AxSYM20.475 0.97 ,0.0001
Immulite = 0.933 Opus21.359 0.85 ,0.0001
AxSYM = 3.508 Opus 2 6.511 0.90 ,0.0001
Vitros = 0.191 AxSYM 2 0.203 0.97 ,0.0001
Vitros = 0.591 Opus 2 0.411 0.88 ,0.0001
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